Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection

the IGNITE Pharmacogenetics Working Group

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: Genotype-guided antiplatelet therapy is increasingly being incorporated into clinical care. The purpose of this study is to determine the extent to which patients initially genotyped for CYP2C19 to guide antiplatelet therapy were prescribed additional medications affected by CYP2C19. Methods: We assembled a cohort of patients from eight sites performing CYP2C19 genotyping to inform antiplatelet therapy. Medication orders were evaluated from time of genotyping through one year. The primary endpoint was the proportion of patients prescribed two or more CYP2C19 substrates. Secondary endpoints were the proportion of patients with a drug–genotype interaction and time to receiving a CYP2C19 substrate. Results: Nine thousand one hundred ninety-one genotyped patients (17% nonwhite) with a mean age of 68 ± 3 years were evaluated; 4701 (51%) of patients received two or more CYP2C19 substrates and 3835 (42%) of patients had a drug–genotype interaction. The average time between genotyping and CYP2C19 substrate other than antiplatelet therapy was 25 ± 10 days. Conclusions: More than half of patients genotyped in the setting of CYP2C19-guided antiplatelet therapy received another medication impacted by CYP2C19 in the following year. Given that genotype is stable for a patient’s lifetime, this finding has implications for cost effectiveness, patient care, and treatment outcomes beyond the indication for which it was originally performed.

Original languageEnglish (US)
Pages (from-to)1898-1902
Number of pages5
JournalGenetics in Medicine
Issue number11
StatePublished - Nov 1 2020
Externally publishedYes


  • CYP2C19
  • pharmacogenetics

ASJC Scopus subject areas

  • Genetics(clinical)


Dive into the research topics of 'Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection'. Together they form a unique fingerprint.

Cite this